Immunotherapy for Glioblastoma: Playing Chess, Not Checkers
- PMID: 29691293
- DOI: 10.1158/1078-0432.CCR-18-0491
Immunotherapy for Glioblastoma: Playing Chess, Not Checkers
Abstract
Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression and tolerance. These pathways are now being identified and their relative contributions explored. Delineating how these pathways are interrelated is paramount to effectively implementing immunotherapy for GBM. Clin Cancer Res; 24(17); 4059-61. ©2018 AACRSee related articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187.
©2018 American Association for Cancer Research.
Comment on
-
Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.Clin Cancer Res. 2018 Sep 1;24(17):4187-4200. doi: 10.1158/1078-0432.CCR-17-2617. Epub 2018 Feb 14. Clin Cancer Res. 2018. PMID: 29444930
-
Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC.Clin Cancer Res. 2018 Sep 1;24(17):4162-4174. doi: 10.1158/1078-0432.CCR-17-3492. Epub 2018 May 18. Clin Cancer Res. 2018. PMID: 29776956
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources